The effects of infusing human alpha-caleltonin gene-related peptide were studied in eight patients with congestive heart failure, five normal rabbits and five rabbits with adrimnyein-induced cardiomyopathy. In patients with heart failure, eatclonin gene-related peptide ranged a dose-dependent increase in cardiac output and decrease in pulnnmary, and systemic vascular resistance and pdmonary artery pressure . The systemic bland prison and right ahial and pulmonary wedge prennares decreased oal5 at The highest infesian rate (1d ngdrg per min), Heart rate remained unchanged . Plasma epinephrine increased (p < 0.05), whereasaldosteeone, Atria][ natrluretic peptide and prolaemin euncentradons decreased Ip < Calcitonin gene-related peptides are a group of recently discovered regulatory neumpeptides with widespread distribution in humans and animals . These peptides are leveled in the central and peripheral nervous system (1-3), the heart and blood vessels (0,5) . Rat and human alpha-calcaonin gene-related peptides have been synthesized and the human peptide is found circulating in blood at relatively high concentrations (6) . In the heart and blood vessels, specific binding sites have been identified (7-9) . Calcitonin gene-related peptide acts on these receptors to exert powerful cardiovascular effects ., including positive chronotropic and inotropic actions on the heart, bypotension and vasodilation in humans and several animals (9-15) . These effects are independent of beta-adrenergic and histaminergic receptors or blockade of prostaglandin synthesis . Calcironin gene-related peptide stimulates the inward calcium current in the bullfrog heart, seemingly mediated by the stimulation of adenyiate cyclase (16) .
The effects of infusing human alpha-caleltonin gene-related peptide were studied in eight patients with congestive heart failure, five normal rabbits and five rabbits with adrimnyein-induced cardiomyopathy. In patients with heart failure, eatclonin gene-related peptide ranged a dose-dependent increase in cardiac output and decrease in pulnnmary, and systemic vascular resistance and pdmonary artery pressure . The systemic bland prison and right ahial and pulmonary wedge prennares decreased oal5 at The highest infesian rate (1d ngdrg per min), Heart rate remained unchanged . Plasma epinephrine increased (p < 0.05), whereasaldosteeone, Atria][ natrluretic peptide and prolaemin euncentradons decreased Ip < Calcitonin gene-related peptides are a group of recently discovered regulatory neumpeptides with widespread distribution in humans and animals . These peptides are leveled in the central and peripheral nervous system (1-3), the heart and blood vessels (0,5) . Rat and human alpha-calcaonin gene-related peptides have been synthesized and the human peptide is found circulating in blood at relatively high concentrations (6) . In the heart and blood vessels, specific binding sites have been identified (7-9) . Calcitonin gene-related peptide acts on these receptors to exert powerful cardiovascular effects ., including positive chronotropic and inotropic actions on the heart, bypotension and vasodilation in humans and several animals (9) (10) (11) (12) (13) (14) (15) . These effects are independent of beta-adrenergic and histaminergic receptors or blockade of prostaglandin synthesis . Calcironin gene-related peptide stimulates the inward calcium current in the bullfrog heart, seemingly mediated by the stimulation of adenyiate cyclase (16) .
In contrast to the vasodilation produced by acetylcholine and sodium nitropmsside, which increase cyclic guane'ine Flour the'Dcpartment of CerdiulouY . Postgraduate Inhalant nt Medical Education and Research, Chrndigarh, India : +Depanerel of Penpheral Pharmacology, Glass Group Research . Ware . Henstard, England : $Department of Cardiac Medicine. National Henn and Lung IasrLule . tendon . En g land : and SCeurdra di Cardiologla and Di .hunk, . Unioerait, di Brescia . Spedali Civili. Brascia, halt . 0.05). Plasma nmepinephrine, resin activity, cerlfaai and growth harness crnnatratiaas remained unchangedIn truth groups of rabbils, the drug decreased blood pressure and Increased cardiac output and heart rate . There was a significant Increase in renal blood flaw (p < 0.05), The peptide did net Wkd the contraction amplitude of human and rabbit ventricular nyacyles.
These findings suggest that eelellonin gene-related peptide Is a vasaddator in The rabbit and bandana with little direct effect on ventricular myocardium. This peptide may be awful in same forms of heart failure .
U Am Call Cardfui 1991; 17:205-l71 monophosphate in the smooth muscle, the effect of calcilonin gene-related peptide is not accompanied by guanosine monophusphate accumulation 1171 and the vasodilalion is nonendothelium-dependent (18) . Intravenous capsaicin stimulates the release of endogenous calcitonin gene-related peptide, causing vasodilation, hypotensian and a depletion of the peptide from nerve fibers in the myocardium and around the coronary vessels (9, 19) . These findings suggest .hat endogenous calcitonin gene-related peptide may play a role in modulating coronary and peripheral vascular tone . Moreover, a combination of the reported positive isotropic effect on the heart and arterial vasodilation may be beneficial in the treatment of congestive heart failure.
In this study, we investigated the effects of infusing human ulpho-ealcitnnin gene-relatedpepilde on 1) hemodynamics and plasma hormone concentrations in patients with severe congestive heart failure; 2) hemadynamics and tissue blood flow in normal and cardiomyopathic rabbits ; and 3) isolated myocytes from normal rabbits and patients undergoing cardiac transplantation or valvular surgery .
Methods

Human Experiments
Study patients . The human studies were carried out in eight patients admitted far the control of congestive heart failure : six were male and two female, with an average age of Heart Association functional class III or 1V) . Edema was present in three patients ; jugular venous pressure was raised in all and the liver was enlarged in seven . All patients had clinical cardiomegaly and a left ventricular third heart sound . Four patients had evidence of mitral regurgitation . The average cardiothoracic ratio was 62 .4 ± 2.6% on chest X-ray study. All routine laboratory investigations, including plasma electrolytes, creatinine and blood urea nitrogen, were within the normal limits. Five patients were taking digoxin (0 .25 mg/day), all were on an oral diuretic drug (average furosemide dose 57 ± 8 mg/day) and three patients were taking captopril (25 mg three times a day). Hemodynamics . Hemodynamics were measured with a Swan-Ganz catheter . Arterial pressure was measured using intraarterial cannulation of the left brachial artery using a 3F teflon catheter (Seldicath) . Pressures were measured with Hewlett-Packard model 1290C transducers and a Hewlett-Packard model 78354A monitor . Cardiac output was determined by thermodilution (SPI445, Gould Idstruments) . Hemodynarnic variables were derived using standard formulas .
Hormone assay . Hormone assays were carried out in a 30 ml blood sample drawn from a forearm vein. Plasma norepinephrine and epinephrine were measured by high performance liquid chromatography with electrochemical detection . Plasma resin activity, atrial natriuretic peptide, aldosterone, cartisol, prolactin and growth hormone were measured by radioimmunoassay ( .0 .21) . Plasma concentrations of calcitonin gene-eclated peptide were measured by nonequilibrium radioimmunoassay employing a commercial kit (ITS, Immunotechnolugy Service Production) . with a standard curve range of 2.5 to 250 pLVml . Plasma samples were assayed after a simple solid-phase extraction CS"-Pak C 10 cartridges) . Analytical recovery of synthetic calcitonin gene-related peptide (128 pg/mu added to plasma before extraction was 60% to 70r/c (mean 677x ; n = 10). The mean concentration of eir ulc :iob alcitunin gcuc-related pcpt: c in human extracted plasma from 20 normal subjects was 11 .3 ± 4 .7 pg/ml (range 2 .5 to 19 .6) .
Protocol . The studies were performed in the postabsorptive state during the afternoon, 3 h after a light lunch and 6 h after the last cardiac medication . Alter instrumentation, patients were allowed to rest in bed for I h . After baseline measurements, a blood sample was Men from a peripheral vein for estimation of basal hormone levels. Infusion of human alpha-calcitonin gene-related peptide (Celltech Ltd .) was then started into a forearm vein using an infusion pump (Harvard Apparatus. model 902), Incremental infusions of calcitonin gene-related peptide at the dose of 0 .8 . 3 .2 and 16 ng/kg per min were made (2 .16 x 10 -`, 8 .3 x 10 ° and 4.2 x 10 -'' mol/kg per min) . The first two doses were infused for 10 min each . Al the end of each 10 min infusion 2(r period, all hemodynamic measurements were recorded . The highest dose of calcitonin gene-related peptide ! 16 nglkg per min) was infused for 20 min. At the end of this period . hemodynamic measuremcnts were repeated and a second blood sample for hormone assay was taken from a peripheral vein of the contralateral arm to that being infused . The infusion was then stopped . Heetodynamic measurements were continued for I h .
The human studies were performed after obtaining written informed consent from the patients . Ethical clearance was obtained from the Hospital Ethics Committee . The animal experiments were in conformity with the position of the American Heart Association on Research Animal Use and was cleared by the Hospital Ethics Comm)ttee .
Animal Experiments
Study animals. Experiments were carried out in two groups of five New Zealand White rabbits, weighing 1 .9 to 3 .1 kg . The first group of five control rabbits received no treatment . The second group of five animals received adriamycin into an car vein at a dose of 1 mglkg body weight, twice weekly for 7 weeks. We i22' previously showed this treatment to cause cardiomyopathy in rabbits. The adriamycin-treated animals were allowed a 2 week injection-free /'cried to recover from the hematologic and renal toxicity . Polyethylene catheters were then implanted into the right atrium, left ventricle and ascending aorta . A specially designed thermistor catheter was inserted into the left femoral artery and advanced into the descending aorta . This was used for determining cardiac output by thermodilution (22) . The surgical technique has been described in detail (22) . Protocol. Forty-eight hours after surgery, the rabbits underwent hemodynamic study in the conscious unrestrained state . Control measurements of heart rate, right atrial pressure • mean aortic pressure, cardiac output and regional blood flow were made . Human alpha-calcitonin gene-related peptide was infused into the right atrium using an infusion pump. The infusion was begun at I x 10 -II mollkg per min. Heart rate, aortic pressure and cardiac sere measured even 2 min. The infusion rate was increased every 5 min unx cardiac output increased by approximately 25% . The final dose was infused for 10 min before hemodynamic measurements were again taken and a second determination of regional blood flow made using different radiolabeled :nicrospheres. The average final dose for the control animals was 4 .06 x 10-10 mol/kg per min compared with 5 .8 x 10-'o mo!ikg per min for the adriamycin-treated animals (p > 0.05) .
The animals were killed using an excess of intravenous pentobarbilone . The heart, brain, kidney, spleen and small samples of small gut, skin and soleus and quadriceps muscles were removed. weighed and processed for radioactive counting t calculate the tissue blood flow and vascular resistance values (22) . Gadolinium-153-and Scandium-46-labeled nicrospheres (New England Nuclear Ltd .) were used (unless stated otherwise) because of their relatively long half-life, different energy spectrum and ease of seporalion in a gamma counter.
Isolated Cardiac Myocytes
Protocol . The direct myocardial effects of calcitonin gene-related peptide were determined in isolated rabbit and human myocytes . Myocytes were isolated front three normal rabbi) hearts by Langendorff perfusion with a low calcium solution (9 samol/litcr), followed by a 2 min perfusion with solution containing collagenase and hyaluronidase (23). Human ventricular myocardial cells were obtained from the explained hearts from two patients with coronary artery disease (left ventricle from a 48 year old man and right ventricle from a 63 year old maul and from the left ventricle of a 62 year old woman at the time of milra : valve replacement . Pieces of ventricle (t00 mg to 3 g) were quickly chopped into cubes of approximately I min' using an array of razor blades . The ventricles were incubated for a total of 12 min at 35'C in 25 to 50 ml of the low calcium medium containing I to 2 µmolditer calcium . The medium was changed three times during this period, and the tissue was stirred by bubbling with 100% oxygen . The low calcium medium was removed by straining with 330 µcool/liter calcium added . followed by two 45 min periods with the protease (pronase) and 30 9amol/liler calcium added, followed by two 45 min periods with the protease omitted and 400 IU/ml of collagenase added . The medium was shaken gently throughout the incubation and kept under an atmosphere of 100% oxygen .
At the end of each 45 min period, the solution containing the dispersed cells was filtered through a 300 µm gauze and centrifuged at 40 x for I to 2 min . Isolated cells were superfused with a modified Krebs-Ifensleit solution containing calcium (I mmol/)iter) equilibrated with 95% oxygen and 5% carbon dioxide at 32 ° 0 .5°C and electrically stimulated (at 0 .5 Hz, 5 ms, suprathreshold voltage), The contraction amplitude of the myocytes was measured in a perspex chamber, using a video camera edge detection system linked ±ACC Vat. 17 . No . I January 1901 . to an inverted microscope (23) . The spatial resolution of the system was I in 256 and the time resolution 20 ms . Contrac . lion was expressed as percent cell shortening .
In the rabbit myocytes, the effects of I x 10 -° to I x 10-7 moliliter of calcitonin gene-related peptide on the percent cell shortening was investigated cumulatively . In four human cells, the effect of I x 10 -7 molditer of calcitonin generelated peptide was measured, whereas in two other cells, the effects of 10 -s and 10 -°mopliter of calcitonin generelated peptide were investigated. Each concentration of calcitonin gene-related peptide was in contact with the cells for 5 min . At the end of the experiment, the effect of calcium (8 mmol/liter) was also investigated . Statistics. Data are expressed as mean t standnrd deviation unless stated otherwise . The probability of the difference between paired and unpaired data was calculated by Student's I test .
Results
Human Fxperimenrs
Hemodynamics (Table 1) . The rest basal hemodynamic data in the eight patients showed severe cardiac dysfunction as judged by reduced cardiac output (1 .6 t 0-27 liters/min per m 2 ) and increased pulmonary artery wedge pressure (23 .5 ± 6.4 mm Hg) and pulmonary and systemic vascular resistance (470 ± 194 and 2,374 ± 309 dynesis per con' . respectively) . The lowest dose of calcitonin gene-related peptide (0.8 ng/kg per min) caused a small (7 .9%) decrease in systemic vascular resistance (p < 0 .005) and a similar increase (7%) in cardiac output (p < 0 .05) ( Fig. I and 2 ). The heart rate did not change . Calcitonin gene-related peptide at the dose of 3 .2 ng/kg per min caused a further reduction in systemic vascular resistance (20%p, p < 0 .002) and increase in cardiac output (24%, p < 0 .002) . At this dose, pulmonary vascular resistance also decreased (71%, p < 0 .004) and there was a slight decrease in the mean pulmonary arterial pressure (5%, p < 0 .05) . Systemic blood pressure did not change. slowly returned toward the basal values, However, even I h after the infusion had been stopped, cardiac output was signifcantly higher (p < 0 .05) and pulmonary wedge pressure and systemic vascular resistance significantly (p < 0 .05) lower than the basal values . There were no complications or side effects during the infusion . In particular, none of the patients complained of flushing of the face or headache and no patient developed any arrhythmia, .
Plasma hormones (Table 2) . Plasma hormone levels before the start of the peptide infusion and at the end of 20 min at 16 ne/kg per min are shown in Table 2 . Basal plasma norepinephrine levels were consistently raised . Although there was considerable individual variation, the average was nearly three times that of control subjects (p < 0 .05). In contrast, epinephrine levels were within normal limits, Plasma renin activity varied greatly, although the mean value was seven times that of control subjects (p < 0 .01) . Aldosterone and cortisol levels also varied widely . Plasma atrial notriureric peptide concentration was raised in every patient (p < 0 .0011. Growth hormone level was raised in all but one patient Ip C 0 .0051 . Serum pmlaetin levels were within the normal range . The average basal level of cakitonin gene-related peptide was increased in the patients (range 12.5 (if 82 .4 pglrnl, mean 36.82 . 27 .61. There were, however, two patients who had levels within the normal range, the values in our normal control subjects being 11 .33 ± 4 .7 pgiml (range 2 .5 to 19.6) . Calcitonin gene-related peptide levels increased to five times the basal value (185 .9 127 .2 pgrml) after infusion at the highest doseCaleitonin gene-related peptide infusion had no effect on plasma norepinephrine. Plasma epinephrine increased significandy from 119 ± 17 to 323 a 137 pg/mt (p < ( ;Z1 . There was no consistent change in plasma renin activity . Plasma uldosleronc decreased in all but one patient ; the mean level decreased from 366 . 135 to 263 t 138 peril (p < 0.021 . Atrial natriuretie peptide decreased in every case ; the average value decreased from 385 t 45 to 250 ± 35 pg)ml (p < OM) . Plasma growth hormone and cortisol did not change . The prolactin levels IACC V01. 17 . Ke . I 1anmry t991S0N-17 decreased in all patients; the average level decreased from 11 .6 t 2 .1 to 9 .59 a 2.1 ng/ml (p < 0.02).
Animal Experiments
Hemodynamics and tissue blood flow (Tables 3 and 4) . Seven weeks of adriamycin treatment caused the development of cardiomyopathy in all five rabbits as judged by a significant reduction in cardiac output (p < 0 .05), increase in the total peripheral resistance (p < 0.05) and a redistribution of tissue bland flow (Table 3) .
Calcitunin gene-related peptide caused a 17% increase in heart rate in the five control animals (p < 0 .05) ( Table 3 , Fig.  3 ) . Although heart rate increased by 10% in the adriamyeintreated group it did not reach a level of significance . Mean blood pressure was reduced by about 30% in both groups (p < 0.051 . There was a significant increase in cardiac output (p < 9 .05), the effect being +31 .2% in the control as compared with +24.5% in the adriamycin-treated animals . Total peripheral resistance decreased significantly by about the same amount in both groups . Stroke volume index increased in both groups, but the difference reached a significant level only in the control group.
Calcitonin gene-related peptide caused a marked increase in renal blood flow in both groups, but the effect was more striking in the adriamycin-treate4 group . Myocardial and skin blood flow was increased t,y calcitonin gene-related peptide, but :he changes did not :each significance in either of the groups . Cerebral blood flow remained unaltered and there was no consistent change in splenic, small gut or skeletal muscle blood flow . The effect on the calculated tissue vascular resistance is shown in Table 4 . Regional vascular resistance generally reflected changes in the tissue blond flow. However, cerebral and myocardial vascular resistance in both groups and the skin resistance in the control group decreased significantly (p < 0 .05) . but these were not accompanied by significant changes in tissue blood decreased significantly in the adriamycin-treated rabbits .
Isolated Cardiac Mvocytes
Contraetlon umplltrde. No increase in contraction amplitude was seen in either the seven rabbit myocytes (three rabbits) or in the four human cells tested (Fig. 4) . The concentration of ceicitonin gcne-related peptide was increased to 10 -' meltliter in all cells and to 10 -s moliliter in two of the human myocytes. Every cell subsequently tested showed increased contraction amplitude in response to raised extracellular calcium, indicating that it had the potential to contract more strongly . The contraction amplitude in a maximally stimulating concentration of calcium (8 mmoll Titer in rabbit, 6 to 15 mmolfliter in human) is shown in Figure 4 . CALCITODtN GENE-RELATED PEPTIDE IN HEART FAILURE 'P < 0 OS, 3p < 0-01 compared wish pre-dog levels, rp < OM edoamccin-ireeted e,J eonud rabbds before drug troelmenl-Data are mean -SD.
Discussion to this study, we report for the first time the effects of infusinns of human calcitnnin gene-related peptide on the hemedynamics and plasma hormone concentrations in paitems with severe congestive bean failure . In Addition, we studied the hemudynamia and regional blood flow in groups of normal and adtiamycin-treated rabbits . To test whether caldi onin gene-related peptide has any direct inotropic effects on the heart . we examined its effects on isolated cardiac myocytes .
Nronan Study
Vasodilalirg effects . In patients with congestive heart failure. infusion of calcitonin gene-related peptide caused a dose-dependent decrease in systemic and pulmonary vascular resist once and an increase in cardiac output. The consid- enable increase in cardiac output probably prevented a decrease in blood pressure until the highest dose (16 nglkg per min) was reached. The two lower doses of the peptide did not cause any change in the left-or right-sided filling pressures of the heart. At the highest dose, both the right alrial and pulmonary arterial wedge pressure decreased . This would suggest that the peptide behaves as an areriotar dilator at low doses and a mixed vasodilator at high doses . Recently, McEwan et al . (24) showed dilation of the forearm resistance vessels in humans in response to direct brachial artery infusion of calcitonin gene-related peptide . blnximal increase in forearm blood flow was obtained with infusion of 1 .2 to to n l0 -' a mallmid of calcitonin gene-related peptide (4 to 40 nglmin) . They were unable to show any venoditation with infusion of up to 5 x 1f -j1 1 moVmin of the peptide (20 nglmin) directly into the vein . This lack of effect on the capacitance vessels, in contrast to a vesodilator effect seen in our patients with the highest dose, may he due to the higher rest venous tone in patients with congestive heart failure or the higher final dose used in our patients . Role of (aehycardia. In normal human volunteers, intravenous calcitonin gene-related peptide bas been shown to cause tachycardia (6, 12, 13, 25) , with either no change (25) or a decrease in systemic blood pressure (6, 12, 13) . The lack of reflex tachycardia in our patients even at the highest dose thin caused a decrease in blood pressure is an interesting observation. Such a response might occur when improvement in hemodynamics is accompanied by a withdrawal of sympathetic overactivity or it might reflect the barnreflex +:D-urmalities seen in patients with congestive hear[ failure (26). Conversely, the absence of a tachycardia response might be the result of a specific effect of this peptide on the : sinus node . Ono et al . (16) have shown that the chronotropic effects of calcitonin gene-related peptide on the heart are mediated through specific receptors that increase transmembrane calcium current (to -s to 10-moVliter), In the presence of the catecholamine isoproterenol, calcitonin generelated peptide has the opposite effect and blocks the isoproterenol-stimulated calcium current . It is likely that in patients with congestive heart failure, the combination of high circulating levels of catecholamines and calcilonin gene-related peptide block the development of lochycardia .
Peptide binding sites . Specific binding sites for calcitonin gene-related peptide have been identified in the heart and blood vessels (91. In the at . the highest concentrations of binding sites for calcitonin gene-related peptide are in the right atrium, followed by the left atrium and right and left ventricles . Positive isotropic effects of calcitonin generelated peptide seen in in vitro studies (9, 27) are probably brought about by direct interaction of calcitonin gene-related peptide with these receptors and are not influenced by adrenergic, histaminergic and prostaglandin synthesis blockade . In most species, the positive isotropic effects of calcitonin gene-rotated peptide are seen in the atria and not in the ventricle (10 .14,15) . In humans, the positive inotropic effect of the peptide could be supressed by labetalol, an alpha-and beta-adrenoceptor blocker (12) , which suggests that the inotropic effect could have been caused by reflex sympathetic stimulation . The effect of calcitonin gene-related peptide on isolated myocytes has never been reported . The lack of any il~ vitro inotopic effect seen in our isolated ventricular myocytes suggests that specific binding sites for this peptide may not he present in the human and rabbit ventricles . The increase in cardiac output seen in our patients and rabbits after calcitonin gene-related peptide infusion is, therefore, most likely due to altered hemadynamics and, in particular . the decrease in afterload.
Hormone Studies
Plasma peptide concentration . The concentrations of plasma hormones in our patients with congestive heart failure are similar to those described previously (2g) . In normal humans . relatively high concentrations of circulating immunoreaclive calcitonin gene-related peptide have been reported (25 to 941 -_ 14 .2 x 10 ° mollliter) (6,291 . We measured calcitonin gene-related peptide using an extraction procedure followed by radioimmunoassay and obtained a mean value of 113 ' 4 .7 pglml . corresponding m 3 n 10-11 r d uirer, much lower than the concentrations described by others (6, 29) . Although the concentration of the peptide was increased in most patients with congestive heart failure, there was considerable individual variation . There was no correlation between the calcitonin generelated peptide concentration and baseline thermodynamics or hormone levels. The increased level of the peptide in patients with congestive heart failure has not been reported previously. The pathophysiologic significance is not dear, but may reflect a role of this peplide in congestive heart failure .
Plasma epinephrine and norepinephrine, Calcitonin generelated peptide infusion caused a significant increase in plasma epinephrine and decrease in aldosterone, atrial natriuretic peptide and prolaetin contentrations . An increase in plasma .pinephrine and norepinephrine levels after calcitonin geese-rotated peptide infusion has been described by others {6.13) and may be related to the decrease in systemic blood pressure and reflex sympathetic activation . Norepinephrtnc did not increase in our patients, This dissociation between epinephrine and norepinephrine levels is unusual and may suggest a direct effect of the peptide on the adrenal medulla. A reduction in atria[ natriuretic peptide seen in every patient was probably due to a decrease ANAND Er AL .
2 1 5 CALCITONIN GENE-RELATED PEPTIDE IN HEART FAILURE in the filling pressures seen with calcilonin gene-related peptide .
Plasmareninandprolactin . Kurta el al. (305 administered calcitonin gene-related peptide to normal human volunteers in doses similar to those used by us and found an increase in plasma renin activity . Plasma aldosterone did not change . They examined the effect of calcitonin gene-related peptide oil isolated juxtaglomerular cells and concluded that the increase in resin secretion was the result of a direct regulatory influence on the juxtaglomerular cells and not necessarily due to a decrease in blood pressure. In our patients, short-term infusion of calcitonin gene-relate .. peptide did not change resin activity, although the plasma aldosterone concentration decreased. The differences in these findings cannot easily be explained . Calcitonin generelated peptide infusion caused a significant decrease in prolaetin levels in our patients . Although the effect of this peptide on pmlactin has not been reported before . calcitasin, which has structural homology with calcitonin gene . related peptide, has been shown to exert an inhibitory effect or prolacim secretion in patients with impaired renal function (31).
Animal Sardv
Adrinmycin eardiamyopathy . We have previously shown (22) that the adriamycin treatment used in this study leads to the development of cardiomyopathy, with reduced cardiac output at rest, a flat Frank-Starling curve . increased total body exchangeable sodium and a redistribution of regional blood flow . This model of low output failure has been successfully applied to study the effect of drugs in the conscious animal at rest 1321 . The hemodynamic and regional blood flow alterations observed in the adriamycintreated animals in this study resembled those report id by us previously (22, 32) and are similar to the changes seen in patients with heart failure (33 .34) .
Hemody, amts effects . In the normal rabbits . calcitonin gene-related peptide in doses that caused hypotension resulted in an increase in cardiac output, heart rate and renal blood flow . Qualitatively similar hemodynamic and tissue blood flow changes were seen in the rabbits with heart failure. In vitro studies have shown considerable variation in the effects of calcitonin gene-related peptide in different species . Thus. whereas it has positive chronulropic and inotropic effects on isolated rat and guinea pig atria. it does not after the rate or force of contraction in the isolated rabbit heap 110 .11). In our study, there was only a modest increase in heart rate in the normal rabbits and no change in the rabbits with heart failure despite a considerable decrease in blood pressure, Effects on renal and peripheral blood flow. Calcitonin gene-related peptide increased renal blood flow and reduced renal vascular resistance in both groups of animals . The renal effects of this peptide, unlike those of utrtal natriurelic peptide, have not been well studied-out an increase in renal olood flow has been shown to occur in the rat (351. The effect of calcilonin gene-related peptide on other vascular beds was not so impressive, This may be in part due To technical factors . Skin and muscle blood flow is very small, so that the reliability of radioactivity counting is reduced . Thus, the suhsmntial percent increase in skin blood flow after calcitonin gene-related peptide did not reach ale vel of significance, whereas the decrease in resistance was significant only in the control animals. These limiting technical factor ; do not apply to the brain • where blood flow is considerable and clearly did not significantly change during infusion of calcitonin gene-related peptide . However, the rcointenae :e of blood flow in the presence of a reduced perfusion rressure implies a degree of vasodilation . Furthermore, there was a significant decr:dse in resistance in the rabbits with cardiomyopathy, which is cansistent with the presence of calcitonin gene-related peptide receptors in the cerebral arteries (7,B).
Conclusion. The present study confirms that calcitonin gene-related peptide exerts powerful pharmacologie effects on the cardiovascular and endocrine systems, but the physiologic significance of these effects remain to be determined . The peptide may act directly through its specific receptors and indirectly by influencing the release and action of other cardiovascular transmitters, Exogenous calcilonin gene-related peptide produced beneficial hemodynamic effects during shorPlernt infusions in patients with severe congestive heart failure and were attributable to vasodilation and not a positive isotropic effect, As yet, there is no report of the development of tachyphylaxis after prolonged infusion . These cardiovascular actions of calcitonin gene-related peptide along with its capacity to increase renal blood flow suggest a useful role in clinical cardiclogy .
